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wileyonlinelibrary.com/journal/bcp25120Aims: Type 1 diabetes can be complicated with neuropathy that involves immune‐
mediated and inflammatory pathways. Glucagon‐like peptide‐1 receptor agonists
such as liraglutide, have shown anti‐inflammatory properties, and thus we hypothe-
sized that long‐term treatment with liraglutide induced diminished inflammation and
thus improved neuronal function.
Methods: The study was a randomized, double‐blinded, placebo‐controlled trial of
adults with type 1 diabetes and confirmed symmetrical polyneuropathy. They were
randomly assigned (1:1) to receive either liraglutide or placebo. Titration was 6 weeks
to 1.2–1.8 mg/d, continuing for 26 weeks. The primary endpoint was change in
latency of early brain evoked potentials. Secondary endpoints were changes in proin-
flammatory cytokines, cortical evoked potential, autonomic function and peripheral
neurophysiological testing.
Results: Thirty‐nine patients completed the study, of whom 19 received liraglutide.
In comparison to placebo, liraglutide reduced interleukin‐6 (−22.6%; 95% confidence
interval [CI]: −38.1, −3.2; P = .025) with concomitant numerical reductions in other
proinflammatory cytokines. However neuronal function was unaltered at the central,
autonomic or peripheral level. Treatment was associated with −3.38 kg (95% CI:
−5.29, −1.48; P < .001] weight loss and a decrease in urine albumin/creatinine ratio
(−40.2%; 95% CI: −60.6, −9.5; P = .02).
Conclusion: Hitherto, diabetic neuropathy has no cure. Speculations can be raised
whether mechanism targeted treatment, e.g. lowering the systemic level of proinflam-- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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• There is no known cure to diabetic neuropathy, which
may affect the central, autonomic or peripheral nervous
systems and consequently reduces life expectancy and
quality of life.
• In preclinical trials, glucagon‐like peptide‐1 agonist
treatment has shown anti‐inflammatory and
neuroprotective effects, and thus possesses a justified
treatment option in diabetic neuropathy.
• Heightened levels of interleukin‐6 have been associated
with reduced heart rate variability in type 1 diabetes,
potentially indicating a specific importance of this
cytokine in autonomic neuropathy.
What this study adds
• Liraglutide elicited a reduction in interleukin‐6 in patients
with long time type 1 diabetes and confirmed
symmetrical polyneuropathy.
• There was a numerical reduction in other cytokines
indicating anti‐inflammatory actions of liraglutide,
however no improvement was shown in neural function,
plausibly because the polyneuropathy had reached a
point beyond reversibility.
• Clinically, liraglutide induced weight loss and improved
microalbuminuria, confirming compliance to the study
drug.1 | INTRODUCTION
Diabetes is a chronic metabolic disorder associated with chronic low‐
grade inflammation, oxidative stress and changes in endoneurial integ-
rity, which can result in several complications such as polyneuropathy.
In type 1 diabetes, the pancreatic islet β cells are the target of an auto-
immune response, which destroys the insulin producing capacity.
Different cytokines have been associated with islet mononuclear infil-
trate and cell toxicity.1 Systemic inflammation is typically quantified by
assessing serum levels of proinflammatory cytokines such as tumour
necrosis factor‐α (TNF‐α) and interleukin (IL)‐1 and IL‐6. Such con-
comitant inflammation has been associated with marked neuronal loss
leading to widespread disturbances in neuronal function in neurode-
generative diseases e.g. in Alzheimer's disease.2 In addition, in vitro
and in vivo studies provide convincing evidence that glucagon‐like
peptide‐1 (GLP‐1) agonists possess anti‐inflammatory and antioxida-
tive effects, putatively mediated alterations in monocyte function,
diminished macrophage infiltrations and subsequent inhibition of pro-
inflammatory pathways.3 Furthermore, preclinical studies of the effect
of GLP‐1 agonists on the central nervous system have demonstrated
beneficial effects on memory, synaptic brain plasticity and glucose
metabolism.4 In addition, experimental animal studies have indicated
that GLP‐ 1 agonists (exenatide) may also exert direct neuroprotective
and neurotrophic effects independent of its glycaemic effects.5-7 For
example, in diabetic and nondiabetic mice, GLP‐1 receptors are pres-
ent on sensory neurons, axons, Schwann cells and dorsal root ganglia.
Diabetic polyneuropathies are common and present in approxi-
mately 50% of adults with long‐term diabetes, the pathogenesis of
which is multifactorial including vascular, metabolic, immune mediated
and inflammatory pathways.8 The clinical manifestations of
polyneuropathy are pleomorphic and are associated with substantial
socioeconomic burdens, and reduced quality of life. Polyneuropathy
affects classically the peripheral axons in a length dependent manner
leading to classical stocking‐and‐glove representation and is termed
diabetic symmetric polyneuropathy (DSPN). These neuropathic
changes coexists often with diabetic autonomic neuropathy and alter-
ations of the structural and functional brain processing, which may be
evident as a reduction in regional grey matter volume, microstructural
damage within nerve tracts, and alterations in processing of somato-
sensory evoked potentials (SEPs).9-11 Despite a negative proof‐of‐
concept study evaluating the effect of exenatide, a GLP‐1 agonist,
on measures of DSPN and cardiac autonomic neuropathy (CAN) inpatients with type 2 diabetes, it is, however, plausible that GLP‐1
agonists via an anti‐inflammatory mechanism could target the
neuroinflammatory component of polyneuropathy, potentially leading
to improved neuronal function of the central and peripheral nervous
system in diabetes.12,13
Therefore, we hypothesized that treatment with a GLP‐1 agonist,
improves neuronal function through diminished inflammation in type
1 diabetes, independent of glucose metabolism. The primary objective
was to explore the neuronal function in response to anti‐inflammatory
actions of liraglutide treatment and thus the secondary aim was to
investigate the effect on inflammatory parameters.
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2.1 | Study population
We performed a prospective, randomized, double‐blinded, parallel‐
group, placebo‐controlled trial at Aalborg University Hospital
from June 2014 to January 2017. Patients were recruited at the
Department of Endocrinology, and potential eligible patients were
prescreened on the basis of a recorded vibration perception threshold
above 18 V. All patients underwent nerve conduction tests to diag-
nose DSPN according to the Toronto criteria not more than 4 weeks
prior to study entering.14 Prior to entering the study, prescribed med-
ication e.g. type of antihypertensive treatment was registered and
within the safety window it was intended to limit alterations in such
medication throughout the study. Additional inclusion criteria were
age over 18 years, a verified diagnosis of type 1 diabetes for a mini-
mum of 2 years: (glycated haemoglobin [HbA1c] ≥6.5% [>48 mmol/
mol]), stable hyperglycaemic medication insuring that patients as min-
imum had received the given treatment (long acting and fast acting
insulin or insulin pump with dosing adjustments according to regi-
mens) for at least 3 months prior to study entrance, body mass
index > 22 kg/m2 and written consent. Exclusion criteria included type
2 diabetes, other neurological disorders than DSPN, estimated glomer-
ular filtration rate < 60 mL/min/1.73 m2; calcitonin >25 ng/L, HbA1c
level < 6.5%, use of GLP‐1 agonists or DPP‐4 inhibitors. Treatments
were masked and appeared identical and were randomly assigned
1:1 liraglutide or placebo in blocks of 8, generated from a randomiza-
tion list provided by the drug supplier. The intervention was titrated
over a 6‐week period to a dose between 1.2–1.8 mg/d, depending
on tolerability. The treatment was continued for a further 26 weeks.
Dropouts/withdrawals were mirror randomized. Ethical approval was
granted by Region Nordjylland, Denmark (N‐20130077) and all partic-
ipants gave written informed consent prior to entry. The study was
registered in public databases (EUDRA CT, ref 2013–004375‐12;
and clinicaltrials.gov, ref NCT02138045) and performed in accordance
with International Council for Harmonization Good Clinical Practice
and the Declaration of Helsinki. All participants underwent multiple
tests over a period of 3 study days at baseline. All experimental proce-
dures were performed between 8 AM and noon. Follow‐up was per-
formed after 26 weeks of intervention.2.1.1 | Central neuronal assessment—electrical stim-
ulation and evoked potentials
Electrical stimulation was applied using surface electrodes
(15 × 15 mm, Neuroline 700, Ambu A/S, Ballerup, Denmark) at the
right median nerve (medial to the palmaris longus tendon and directly
proximal to the right wrist) in order to elicit somatosensory evoked
potential (SEP). A computer‐controlled electrical stimulator (Noxitest
IES 230, Aalborg, Denmark) using bespoke software (LabVIEW, Cus-
tom made at Aalborg University, Denmark) delivered the electrical
stimulus. The threshold at which thumb twitching was evident wasfound by slowly increasing the stimulus intensity in increments of
1 mA. Stimulus intensity was set at 1 mA above the twitch threshold
and were delivered at 1 mA above the threshold in 2 trials of 1000
square pulses (0.2 ms, 2.3 Hz) at baseline and after 26 weeks of treat-
ment at final dose.
The peripheral and spinal neuronal activity was recorded through
surface Ag/AgCl electrodes (Neuroline 710; Ambu A/S, Ballerup,
Denmark). The recording electrodes were located on the ipsilateral
Erb's point and referenced to the contralateral Erb's point. Addition-
ally, recording electrodes were located over the C7 cervical spinous
process (Cv7) referenced to an electrode placed above the jugular
notch but below the glottis. The skin was lightly scratched with sand-
paper at the location of each electrode to remove dead skin cells, in
order to ensure the best possible recordings and the electrode imped-
ance was kept below 2 kΩ. The data were recorded continuously at
20 kHz (SynAmp, Neuroscan, El Paso, TX, USA) and stored offline
for analysis. Electroencephalographic signals were recorded with the
Neuroscan System (Version 4.5; Compumedics, Charlotte, NC,
USA) from 62 surface cylindrical Ag/AgCl scalp electrodes, by use of
the extended 10–20 system montage (Quik‐Cap International;
Compumedics). All participants were seated in supine position with
their legs supported and eyes open during the entire recording. Con-
ductive electrode gel was applied in each electrode to reduce the
impedance below 10 kΩ, which was monitored using proprietary soft-
ware (Neuroscan, Version 4.3.1; Compumedics). The electroencepha-
lograph was recorded as continuous files with open online filters
with a sampling rate of 1 kHz and stored for further analysis of electri-
cally elicited evoked potentials. Assessment of SEPs is a reliable objec-
tive method for following upstream activity from the periphery to the
spinal cord, to the brainstem and finally to the cortex. The reference
electrode was situated between AFz and Fz, and therefore the polarity
is inverted (e.g. our N14 corresponds to is P14 in other work15). Early
cortical activation was analysed at the negative potential (N20) and
the positive potential (P22), at the centro‐parietal CP5 electrode con-
tralateral to the stimulation, and the peak‐to‐peak amplitude was
used. In a similar way the latencies and amplitude of the subcortical
response (N14‐P18) was analysed at the occipital midline electrode
(Oz), and late cortical response (N60‐P80) was assessed at the central
midline electrode C1.16
2.1.2 | Systemic biochemistry, inflammatory profile
and macrophage function
Routine laboratory tests to monitor e.g. HbA1c, cholesterol and tri-
glycerides were analysed at the Department of Clinical Biochemistry,
Aalborg University Hospital. Fasting venous blood was collected and
subsequently centrifuged at 800 g for 10 minutes at room tempera-
ture. Plasma was immediately frozen at −80°C. Levels of proinflamma-
tory cytokines (IL1β, TNF‐α, IL‐6, IL‐8, IL‐10) were analysed by using a
multiplex cytokine assay (Meso‐Scale Discovery, Rockville, MD, USA)
and specific macrophage markers (sCD163 and sCD206) were
analysed by enzyme‐linked immunosorbent assay at Department of
Clinical Biochemistry at Aarhus University Hospital.
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cardiometric derived autonomic measures
Twenty‐four‐hour Holter monitoring electrocardiographic recordings
were undertaken (Lifecard CF; Del Mar Reynolds, Spacelabs
Healthcare Inc., Snoqualmie, WA, USA), according to internationally
recommended standard.17 The initial recording period comprised a
10‐minute epoch where participants were instructed to relax followed
by 2 × 15‐minute periods of guided respiratory rate of 15 breaths/min
in the supine position followed by the same respiration rate in stand-
ing position. Blood pressure was simultaneously measured noninva-
sively in these 2 positions (Omron M4, Hoofddorp, Netherlands).
Orthostatic hypotension was defined as >20 mmHg reduction in sys-
tolic blood pressure on standing. Twenty‐four‐hour heart rate variabil-
ity (HRV) was assessed (Impresario Software version 3; Spacelabs
Healthcare Inc., Snoqualmie, WA, USA), deriving HRV indices from
within 5‐minute cycles of R‐R‐intervals. The following time domain
HRV indices were obtained: standard deviation of the averages
of NN intervals in all 5‐minute segments of a 24‐hour recording,
reflecting autonomic imbalance (both sympathetic and parasympa-
thetic tone); and the root mean square of difference of successive nor-
mal R‐R intervals reflecting parasympathetic tone.18 In addition, fast
Fourier transformation provided the following frequency domain
HRV indices: derived total power, very low frequency, low frequency,
high frequency and the low/high frequency ratio (reflecting
sympatico–vagal balance). All HRV indices were adjusted for baseline
heart rate.19 Furthermore, validated measures of cardiac vagal tone
and cardiac sensitivity to the baroreflex were derived.20 Both cardiac
vagal tone and cardiac sensitivity to the baroreceptor are real time
measures of efferent and afferent brainstem influence on the heart
(Neuroscope, MediFit Instruments, Enfield, Essex, UK). The comple-
mentarity of these measures in diabetes are described in detail
elsewhere.18
2.1.4 | Peripheral neuronal assessment—peripheral
nerve function
Nerve conduction studies was evaluated by use of standardized neu-
rophysiological testing by trained neurophysiologists, according to
American Association of Electrodiagnostic Medicine.21 Assessments
of nerve conduction velocities, amplitudes and F‐waves were per-
formed on the motor nerves (peroneal, tibial and ulnar nerves) and
sensory nerves (sural, radial and median). To avoid influence of
skin‐temperature on the conduction velocity, appropriate warming
measures were used to ensure that the testing room did not allow
skin temperatures below 32°C. Spring‐ring electrodes were used to
record digital sensory nerve action potential. A plastic bar electrode
was used for all other nerves. The results were processed according
to reference values accepted by our EMG laboratories. To evaluate
the severity of large fibre neuropathy, a composite score consisting
of numerical ratings from 5 components of the sural, peroneal and
tibial nerve assessment was used (range 0–15), where a total of 3
points indicate DSPN.22Small fibre neuropathy was measured by a computerized Thermo
Tester (TSA II NeuroSensory analyser; Medoc Ltd, Ramat Yishai,
Israel). The temperature increased from a baseline of 32°C to a maxi-
mum of 52°C with increments of 1°C/s. The thermode was positioned
on the skin on the right volar forearm, 10 cm proximal from the wrist.
At pain tolerance threshold, the participants were told to press a
button and the average of 3 successive stimulations were used for fur-
ther analysis.
Loss of protective sensation was assessed by applying a standard-
ized 26‐g monofilament perpendicular to the plantar side of the
first toe and a reference area on the forearm. The size of the monofil-
ament (gram) was noted at the pain detection threshold. If no pain
was evoked at the maximum size, 300 g was notified for further
calculation.2.2 | Study endpoints
The primary endpoint was the change in the early precortical N20
latency of the primary SEP elicited in response to electrical stimuli deliv-
ered to the median nerve before and after 26 weeks of placebo‐
controlled intervention at the titrated dose.23 The secondary outcomes
were changes in systemic proinflammatory cytokines (IL‐1β, TNF‐α, IL‐
6, IL‐8 and IL‐10) and specific macrophage markers (sCD163 and
sCD206), subcortical evoked potentials (N14) and late cortical poten-
tials (N60), measures of autonomic function, and standardized neuro-
physiological testing. Tertiary outcomes were alterations in weight,
HbA1c, heart rate, blood pressure and insulin utilization.2.3 | Statistics
The sample size was determined according to previously reported
electrophysiological latencies from our laboratory. However, these
results were not specific to liraglutide‐induced changes. This study
was powered to detect a minimal difference of 1.0 standard devia-
tion (SD) between liraglutide and placebo in the N20 latency and
amplitude. With 80% power and a 2‐sided significance level of
0.05 the sample size needed to detect this change is 16 in each
group or 32 patients in total, assuming a 20% SD in recorded laten-
cies. Factoring in an attrition rate of 25% we set a sample size of 20
patients per group.
Patient characteristics are presented as means with SD or as
medians with interquartile range (IQR) according to whether data
followed the normal distribution or not. Group differences at baseline
were assessed by Student t test and χ2 test for categorical variables.
Effects of liraglutide versus placebo were modelled by linear
regression adjusting for baseline variables of study outcomes. To fulfil
the requirement of a normal distribution of the model residuals, out-
comes were log‐transformed when applicable. Consequently, esti-
mates for these models are given in percentages. Where outcomes
where not log transformed estimates are reported as absolute values.
HRV indices were adjusted for resting heart rate at the time of testing.
Statistical significance was inferred at a 2‐tailed P‐value <.05. Analyses
BROCK ET AL.2516were performed prior to unblinding, using SAS version 9.4 (SAS Insti-
tute, Cary, NC, USA).3 | RESULTS
In total, 602 patients with type 1 diabetes were identified in the elec-
tronic patient records; however, 488 did not meet the specific inclu-
sion criteria (Figure 1).
The study personnel assessed the 114 remaining patients for
additional eligibility. Of these, 66 patients were excluded (n = 20,
did not have abnormal nerve conduction velocities and n = 46
declined to participate). Ultimately, 48 patients were randomized, 9
of whom withdrew from the study due to adverse effects (7/9:
severe nausea; 5/9: vomiting; 3/9: reflux; 3/9: decreased appetite).
In total 19 patients randomized to liraglutide and 20 to placebo
completed the trial. Overall, 80% of patients were male, had a mean
(SD) age of 50.4 years (8.6), a diabetes duration of 32.4 years (9.3), a
HbA1c of 66 mmol/mol (IQR 58–73) ~8.2% (IQR 7.5–8.8) and 35
patients (90%) had orthostatic hypotension. The baseline characteris-
tics of the 2 study groups are shown in Table 1. No between group
differences were identified in the clinical evaluation of severity of
DSPN, conduction velocities or amplitudes. Moreover, no differences
between groups were shown in baseline characteristics including
sex distribution, age, HbA1c, body mass index, diabetes duration,
blood pressure, kidney function, cholesterol, smoking habits or use
of medication except intermediate‐acting insulin and insulin pump
therapy.FIGURE 1 The consort flow chart shows the progress through this prospe3.1 | Primary study endpoint
3.1.1 | Central neuronal assessment—evoked
potentials
Twenty‐six weeks of intervention with liraglutide did not demonstrate
changes in early precortical N‐20 latency from electrically evoked
brain potentials with a difference of −1.5% (95% confidence interval
[CI]: −10.0, 8.0), see Figure 2 and Supplementary Table S1.3.2 | Secondary endpoints
3.2.1 | Inflammatory profile
Liraglutide significantly reduced IL‐6 (−22.6% (95%CI −38.1, −3.2)
compared to placebo with a numerical reduction in other proinflam-
matory cytokines and markers of macrophage function (Figure 3 and
Table 2A).3.3 | Central neuronal assessment—evoked
potentials
There were no differences in either latency or amplitude in the
upstream activation of the brain across a number of levels including
sub‐, early‐ and late‐cortical activation, see Figure 2 and supplemen-
tary material.ctive, randomized, double‐blind, parallel‐group, placebo‐controlled trial
TABLE 1 Baseline characteristics
Liraglutide (n = 19) Placebo (n = 20) P‐values (group difference)
Demographics
Sex (male) 17/90 14/70 .121
Age (y) 51 (10) 50 (8) .577
Weight (kg) 93 (17) 92 (17) .945
Body mass index (kg/m2) 29 (4) 29 (5) .779
Diabetes duration (y), range 31 (24–43) 32 (26–40) .963
Regular smoking 4/25 4/22 .849
Distal symmetrical polyneuropathy
Sural nerve conduction velocity (m/s) 42 (41–44) 43 (39–47) .914
Sural nerve amplitude (mV) 2.2 (1.7–3) 3.0 (1.8–4.0) .821
Tibial nerve conduction velocity (m/s) 42 (35–45) 39 (35–43) .243
Tibial nerve amplitude (mV) 3.3 (1.6–4.7) 1.2 (0.8–1.7) .255
Median nerve conduction velocity (m/s) 51 (47–53) 49 (46–51) .365
Median nerve amplitude (mV) 9.0 (7.8–10.2) 8.3 (7.3:9.3) .342
Severity neuropathy composite score 9.7 (7.1–12.2) 8.7 (6.5–10.8) .523
Michigan neuropathy screening instrument 2.8 (1.9–3.7) 2.9 (1.7:4.0) .933
Biothesiometry (V) 38.3 (13.8) 34.2 (13.7) .350
Thermal pain tolerance threshold (°C) 48.3 (2.2) 46.6 (4.3) .132
Monofilament size to evoke pain (g) 271 (20) 294 (6) .267
Cardiac derived parameters
Systolic blood pressure (mmHg) 153 (16) 150 (16) .475
Diastolic blood pressure (mmHg) 84 (13) 84 (10) .851
Orthostatic hypotension 18/95 17/85 .310
Clinical biochemistry
eGFR (CKD‐epi) 85 (65–90) 85 (72–90) .867
HbA1c (mmol/mol) 69 (59–80) 63 (57–71) .122
HbA1c (%) 8.5 (7.5–9.5) 7.9 (7.3–8.6) .122
Urinary albumin excretion rate (mg/24‐hour) 78 (23–554) 33 (27–235) .413
Total cholesterol (mmol/L) 4.4 (0.8) 4.6 (0.6) .493
HDL cholesterol (mmol/L) 1.5 (0.5) 1.6 (0.4) .541
LDL cholesterol (mmol/L) 2.4 (0.6) 2.5 (0.5) .248
Triglycerides (mmol/L) 0.8 (0.7–1.2) 0.9 (0.7–1.1) .431
Medication
Fast‐acting insulin 17/90 17/85 .675
Intermediate‐acting insulin 3/16 0/0 n/a
Long‐acting insulin 9/47 9/45 .882
Insulin pump therapy 1/5 6/30 .034
Statins 7/37 10/50 .403
Diuretics 3/16 3/15 .946
Beta blocker 4/21 2/10 .333
RAAS blockade 10/53 8/40 .425
Data are means (standard deviation), median (interquartile range) or n/%. eGFR = estimated glomerular filtration rate (mL/min/1.73 m2); RAAS = renin
angiotensin aldosterone system; HbA1c = glycated haemoglobin.
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FIGURE 2 Grand mean averages of the cortical evoked potentials from 3 different electrodes, representing the subcortical activation (Oz), the
early cortical activation (CP5) and the late cortical activation (C1). It can be seen that there is no difference between liraglutide and placebo in
latencies and amplitudes
BROCK ET AL.25183.4 | Autonomic neuronal assessment—cardiometric
derived autonomic measures
Liraglutide treatment did not elicit any alterations in cardiometrically
derived autonomic measures compared to placebo (Supplementary
material).3.5 | Peripheral neuronal assessment—peripheral
nerve function
Liraglutide treatment was not associated with changes in peripheral
nerve function, (Table 2B).
Liraglutide treatment resulted in a weight reduction of 3.38 kg
(95%CI −5.29, −1.48, P < .001) when compared to placebo regardless
of any effect on HbA1c or total insulin use. Furthermore liraglutidereduced urine albumin‐to‐creatinine ratio by 40.3% (95%CI: −60.6,
−9.5, P = .015; for more details see Table 3).4 | DISCUSSION
Twenty‐six weeks of liraglutide treatment reduced the systemic level
of the proinflammatory cytokine IL‐6, and a similar numerical trend
for other proinflammatory cytokines was found, suggesting a potential
systemic anti‐inflammatory effect. The liraglutide induced in average
3 kg weight loss and reduced urine albumin‐to‐creatinine ratio by
40%. Changes in IL‐6 were interestingly independent of glycaemic
control as well as renal function, however associated to the weight
loss. No treatment group‐differences with regards to improvement
or decline in any electrophysiological measures to assess the neuronal
function was shown.
TABLE 2A Inflammatory profile
Randomization Week 26 group differences
P‐valueLiraglutide Placebo Liraglutide Placebo Liraglutide vs placebo
IFN‐y 11.6 (7.6, 21.55) 7.81 (5.42, 16.45) 7.67 (5.96, 13.8) 9.47 (5.21, 12.6) −18.7% (−47.6, 26.1) .354
IL‐10 0.49 (0.31, 0.64) 0.39 (0.35, 0.59) 0.38 (0.32, 0.63) 0.41 (0.3, 0.63) −7.2% (−26.4, 17.0) .528
IL‐6 1.18 (0.73, 2.06) 0.94 (0.79, 1.45) 0.84 (0.64, 1.12) 1.00 (0.79, 1.44) −22.6% (−38.1, −3.2) .025
IL‐8 13.6 (11.85, 16.8) 13.43 (11.43, 17.65) 14.35 (10.25, 16.1) 14.35 (12, 20.35) −5.8% (−20.3, 11.3) .483
TNF‐a 3.27 (3, 4.01) 2.91 (2.67, 3.58) 3.21 (2.95, 3.87) 3.01 (2.64, 3.42) 3.8% (−4.4, 12.8) .369
CD206 0.3 (0.23, 0.33) 0.21 (0.18, 0.26) 0.27 (0.25, 0.35) 0.21 (0.19, 0.25) −5.3% (−12.3, 2.3) .167
CD163 2.03 (1.63, 2.81) 1.88 (1.5, 2.51) 1.88 (1.6, 2.56) 1.87 (1.58, 2.39) −1.8% (−7.5, 4.1) .536
The proinflammatory cytokines and macrophages markers in response 26 weeks of liraglutide treatment are secondary endpoints. Data are expressed as
mean (standard deviation) or median and (interquartile range). Estimates of test for treatment effect are in % or absolute values (95%CL) [P values for group
difference]. IFN = interferon; IL = interleukin; TNF = tumour necrosis factor; UACR = urine albumin/creatinine ratio; eGFR = estimated glomerular filtration
rate. Concentration for IFN‐γ, IL‐10, IL‐6, IL‐8 and TNF‐α are pg/mL. Concentration of CD206 and CD163 are mg/L.
TABLE 2B Inflammatory profile adjusted for confounding
Controlled for weight Controlled for HbA1C Controlled for UACR Controlled for eGFR
Group difference** P‐value** Group difference* P‐value* Group difference** P‐value** Group difference P‐value*
IFN‐y 7.0% (−33.3, 71.6) .780 −21.3% (−49.2, 22.0) .284 −22.8% (−51.1, 21.9) .267 −20.1% (−48.6, 24.1) .317
IL‐10 −2.4% (−25.0, 27.) .857 −9.9% (−28.6, 13.5) .376 −8.2% (−28.3, 17.4) .495 −8.4% (−27.7, 15.9) .465
IL‐6 −18.0% (−36.4, 5.7) .125 −25.7% (−39.7, –8.4) .005 −24.1% (−40, −4.1) .021 −23.8% (−39.2, −4.5) .018
IL‐8 −2.5% (−19.4, 18.1) .799 −7.9% (−22.2, 9.1) .343 −4.6% (−19.9, 13.6) .595 −8.1% (−22, 8.2) .308
TNF‐a 9.1% (−0.4, 19.4) .060 3.4% (−4.5, 12.0) .408 3.9% (−4.3, 12.8) .366 3.2% (−4.6, 11.7) .431
CD206 −2.0% (−10.1, 6.8) .639 −5.7% (−12.7, 1.8) .135 −0.9% (−6.6, 5.1) .755 −2.2% (−7.8, 3.8) .465
CD163 1.3% (−5.0, 7.9) .699 −1.9% (−7.6, 4.1) .525 −3.6% (−10.7, 4) .340 −5.6% (−12.5, 1.8) .137
Models have been adjusted for baseline values of the given outcome, and adjusted for: (i) change in weight; (ii) change in HbA1C; (iii) change in UACR; and
(iv) change in eGFR during trial. IFN = interferon; IL = interleukin; TNF = tumour necrosis factor; UACR = urine albumin/creatinine ratio.*P < 0.05;
**P < 0.01.
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FIGURE 3 Liraglutide reduced systemic
proinflammatory markers, here shown as
relative differences in comparison to placebo.
The reduction reached significance for
interleukin (IL)‐6; however, a similar numerical
trend was present for other proinflammatory
cytokines, suggesting a potential systemic
anti‐inflammatory effect of the glucagon‐like
peptide‐1‐agonist. The error bars illustrate the
95% confidence intervals. IFN = interferon;
TNF = tumour necrosis factor
TABLE 3 Clinical outcome
Randomization Week 26 group differences
P‐
valueLiraglutide Placebo Liraglutide Placebo Liraglutide vs placebo
Weight (kg) 92.5 (16.5) 92.1 (17.2) 88.5 (17.1) 91.6 (16.1) −3.38 (−5.29, −1.48) <.001
HbA1c (mmol/mol) 69.0 (59.0, 80.0) 63.0 (56.5, 71.0) 72.0 (66.0, 74.) 66.0 (60.0, 73.5) 1.18% (−4.31, 6.98) .681
Total insulin use (IU/d) 55.0 (44.0, 82.0) 44.0 (390.0, 68.0) 50.0 (39.0, 73.0) 43.0 (38.5, 63.0) −1.57% (−18.14, 18.34) .866
UACR 17.99 (7.55, 53.88) 8.5 (4.42, 13.87) 12.41 (8.91, 25.24 8.53 (6.5, 14.8) −40.25% (−60.57, −9.48) .015
eGFR 85 (65, 90) 85 (71.5, 90) 90 (63, 90) 90 (71, 90) −1.49% (−6.78, 4.11) .595
Tertiary endpoints, showing the data are median (interquartile range). Estimates of test for treatment effect are in % or absolute values (95% confidence
interval); P‐values for group difference. Models have been adjusted for baseline values of the given outcome. UACR = urine albumin/creatinine ratio;
eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin.
BROCK ET AL.2520To the best of our knowledge, this is the first time that a random-
ized placebo‐controlled study has shown significant decrease in IL‐6 in
response to liraglutide treatment in humans. Although IL‐6 primarily is
regarded as a proinflammatory cytokine, its actions are not limited to
the immune system and its regenerative properties are increasingly
recognized including neuronal differentiation and regeneration, meta-
bolic processes, and liver regeneration.24 The current findings indicate
a GLP‐1‐mediated reduction in macrophage infiltration and inhibition
of inflammatory pathways, although it is not clear why there was a
preferential effect on IL‐6 rather than other proinflammatory cyto-
kines. It is known that macrophages residing in adipose tissue are
the major sources for elevated plasma IL‐6 in obesity, and therefore
the observed reduction in IL‐6 seems directly influenced by the
weight loss itself.25 Nevertheless, heightened levels of IL‐6 have been
associated with reduced heart rate variability in type 1 diabetes,
potentially indicating a specific importance of this cytokine in auto-
nomic neuropathy.26 Furthermore, elevated levels of IL‐6 have been
identified as an independent predictor of type 2 diabetes and associ-
ated cardiovascular events.27,28 In addition, it has recently been sug-
gested that the inflammatory cascade from CRP to IL‐6 provides a
novel therapeutic opportunity of atheroprotection by targeting the
central IL‐6 signalling system and thus ultimately inhibits the IL‐1β
producing inflammasome.29 Concomitantly with the reduction in
IL‐6 were numerical trends present in other cytokines. This is in
line with the presence of GLP‐1 receptors demonstrated on
monocytes/macrophages and supports the reported 12% reduction
of TNF‐α in liraglutide treated patients with type 2 diabetes and
microalbuminuria.30 The shown reduction of microalbuminuria in the
liraglutide treated group is in accordance with previous data from
the larger outcome studies.31,32 In addition, recent findings advocate
that the IL‐6 pathway seems overactive in 40% of type 1 diabetes
patients and that this previously has been implicated in the initiation
and progression of microalbuminuria.33 In that context, our data show
a concomitantly reduction in IL‐6 and microalbuminuria in type 1 dia-
betes and confirmed DSPN and thus may contribute to a mechanistic
understanding of the liraglutide induced nephroprotection.
The pathogenesis of diabetic neuropathies is complex and poorly
understood, involving vascular, metabolic, immune‐mediated and
inflammatory pathways, which taken together leads to ischaemia,
oxidative stress, nonenzymatic glycation of neural structures andheightened inflammatory response.8 The microglia produces proin-
flammatory cytokines such as IL‐6 and free radicals, which have
been shown to be neurotoxic in e.g. Alzheimer's disease.34 Further-
more, increased levels of TNF‐α has been correlated to heart rate
variability and CAN,35 and are speculated to play a pathogenic role
in the development and maintenance of diabetic neuropathy.36 It is
therefore intriguing to target the anti‐inflammatory component of
neurodegeneration,37 which is emphasized by the promising results
in Parkinson's disease, where activation of the GLP‐1 axis led to
positive effects on practically defined off‐medication motor scores.38
The neuronal damage in diabetes is arguably being the final cumula-
tive downstream effect and thus subtle changes in neuronal function
may not be detectable with current techniques.
To investigate the anti‐inflammatory effect of liraglutide on periph-
eral and central neuronal function, we used the latency of the primary
SEPs to median nerve stimulation—the N20 peak—as the primary out-
come, because it the most consistent peak reaching the pre‐cortical
level, encompassing neuronal transduction, transmission, neuronal
communication and central synaptic plasticity. Furthermore, this peak
also shows low latency variability between subjects. In addition, the
absence of the N20 component is considered the most reliable indica-
tor of unfavourable prognosis in stroke and post‐cardiopulmonary
arrest. To investigate where and when the anti‐inflammatory actions
influence the neuronal communication within the neuroaxis, detailed
neurophysiological information is needed. However, the data in this
study do not support a differentiated interpretation. Given that the
severity score ranged from 3–15, we postulate that some of the
patients had late‐stage neuropathy characterized by de‐myelinization
and axonal loss beyond the point of possible reversibility, which
may have hampered the assessment. We cannot explain the over‐
representation of men, as the literature report ambiguous results on
the influence of sex on development of DSPN39,40; however, the
onset of DSPN is earlier in men plausibly due to lifestyle and depletion
of androgens, which exerts specific neuroprotective effects.41,42
Therefore, the skewed sex distribution rather represents selection
bias, possibly because men have favoured participating in a
resource‐demanding study with many applied technologies.
Similarly, liraglutide failed to have any beneficial effect on the sec-
ondary outcomes of cardiometrically derived parameters of autonomic
function and standardized neurophysiological peripheral nerve testing.
BROCK ET AL. 2521Our HRV results repeated after 26 weeks are in contrast to the find-
ings of a previous studies, which demonstrated a reduction in HRV
in type 2 diabetic patients treated for 12 weeks with liraglutide.43 It
was proposed that the reduction in HRV was secondary to GLP‐1
receptor activation by liraglutide in the sinoatrial node, resulting in a
more chronometric heart rhythm.43 However, reduced HRV has been
shown to be associated with altered central processing within the
operculum–insular network, underlining the systemic influence of dia-
betic neuropathy.9 This discordance in findings may reflect differences
in diabetic disease phenotype and study design. In addition, patient
enrolled in the present study may suffer from manifest and irreversible
CAN as 35/39 participants were diagnosed with orthostatic hypoten-
sion, suggesting co‐existence of severe CAN. This finding is in accor-
dance with a similar trial performed in adults with type 2 diabetes
and mild neuropathy.13 Finally, the tertiary outcomes showed that
liraglutide in comparison to placebo induced weight loss, which con-
firms the drug compliance. Weight loss is considered as anti‐
inflammatory in itself, and it has previously been shown that substan-
tially weight reduction in morbidly obese patients induces a significant
decrease in IL‐6, whereas TNF‐α remains unaltered.44 In this study,
the average weight loss was only approximately 3 kg; however, this
reduction seemed associated with the reduction in IL‐6. The novel
aspect of this study was the utilization of a broad range of techniques
to evaluate the effect of liraglutide in a multi‐level neurophysiological
model. Taken together, liraglutide treatment consistently failed
to demonstrate any reversibility or attenuation of progression of
polyneuropathy in this cohort but then again, patients were recruited
based on severe DSPN, which may not be at a reversible state.
There are several limitations to our study. First, the extern validity
or generalizability to other phenotypes of diabetes is unclear and with
a relatively short intervention of 26 weeks the study design does not
allow for differentiating between the drug effect in either the short or
long term. Consequently, there is a risk of obscuring a real positive
long‐term neuroprotective effect of liraglutide. If that is the case, the
conclusion of the paper has major implications, both generally (publi-
cation bias in preclinical trials) and specifically on the future studies
of diabetic neuropathy. Second, these patients had in average–long
duration (>31 years) of diabetes, which was present prior to guidelines
advocating for intensive glycaemic control and therefore longstanding
and more severe neuropathy may reasonably be expected in this sub-
population. Even though experimental evidence indicates that GLP‐1
agonists may have direct neurotrophic effects, we acknowledge that
the design of including adults with established neuropathy, expectedly
represents disease progression where neuronal changes are at irre-
versible state. Third, choice of measuring the net neuronal function
by the use of SEPs and anticipating a clinical difference of a standard
deviation may have opposed our hypothesis, and have obscured a
true effect (Type I error). Fourth, this study did not investigate
neuroregenerative or neuroprotective response to liraglutide, as for
instance investigating thin fibre regeneration, density or morphology
in skin biopsies or corneal confocal microscopy. These measures could,
however, in contrast to the current study, yield the potential to iden-
tify the warranted anti‐inflammatory effect in early stage neuropathy.Fifth, the plasma levels of cytokines are continuously influenced by
different cascades of signalling transduction and thus the plasma
levels are susceptible to changes in glycaemic control, metabolism
and medication. However severe events including major infections
and hospitalizations are ruled out due to systematic reports of adverse
events. Finally, despite of an overall goal of optimizing treatment, all
participants in this study had relatively high levels of HbA1c in both
placebo‐ and liraglutide‐treated patients. Such hyperglycaemic levels
are, in themselves, proinflammatory and thus could counteract a
liraglutide‐induced anti‐inflammatory effect.5 | CONCLUSION
Liraglutide reduced IL‐6 but did not improve neuronal function, possi-
bly because the polyneuropathy had reached a point beyond revers-
ibility. Hitherto, diabetic neuropathy has no cure. Thus, speculations
can be raised whether mechanism targeted treatment, e.g. lowering
the systemic level of proinflammatory cytokines may lead to preven-
tion or treatment of the neuroinflammatory component in early stages
of diabetic neuropathy. If ever successful, this would serve as an
example of how fundamental mechanistic principles are translated into
clinical practice similar to those applied in the cardiovascular and
nephrological clinic for the benefit of future patients.ACKNOWLEDGEMENTS
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